^
Association details:
| Biomarker: | EGFR exon 19 deletion + MET Amplification + MET D1228V |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) + Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Excerpt:
...we present a case of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET, who after progression on erlotinib responded dramatically to combined MET and EGFR inhibition with savolitinib and osimertinib...When resistance developed to this combination, a new MET kinase domain mutation, D1228V, was detected....the patient was started on off-label therapy with erlotinib (100 mg once daily), which the patient's cancer had previously been refractory to, in combination with the type II MET inhibitor cabozantinib (60 mg once daily)....scans after 4 weeks on combination therapy demonstrated a dramatic response in her progressive lung disease...
DOI:
10.1158/2159-8290.CD-16-0686
